Enrollment to this study was extended by 6 months to allow enrollment of 40 patients at 14 institutions because some high PD-L1 TPS patients were ineligible due to the risk of hemoptysis caused by tumor necrosis and cavity formation. This evidence concerns the gene CD274 and neoplasm.